Protalix BioTherapeutics, Inc.

NYSEAM:PLX Stock Report

Market Cap: US$134.7m

Protalix BioTherapeutics Future Growth

Future criteria checks 5/6

Protalix BioTherapeutics is forecast to grow earnings and revenue by 118.3% and 58.9% per annum respectively while EPS is expected to grow by 118.1% per annum.

Key information

118.3%

Earnings growth rate

118.1%

EPS growth rate

Biotechs earnings growth27.7%
Revenue growth rate58.9%
Future return on equityn/a
Analyst coverage

Low

Last updated15 Nov 2024

Recent future growth updates

Analysts Expect Protalix BioTherapeutics, Inc. (NYSEMKT:PLX) To Breakeven Soon

Feb 22
Analysts Expect Protalix BioTherapeutics, Inc. (NYSEMKT:PLX) To Breakeven Soon

Recent updates

Analysts Expect Protalix BioTherapeutics, Inc. (NYSEMKT:PLX) To Breakeven Soon

Feb 22
Analysts Expect Protalix BioTherapeutics, Inc. (NYSEMKT:PLX) To Breakeven Soon

Have Insiders Been Buying Protalix BioTherapeutics, Inc. (NYSEMKT:PLX) Shares This Year?

Jan 14
Have Insiders Been Buying Protalix BioTherapeutics, Inc. (NYSEMKT:PLX) Shares This Year?

Could The Protalix BioTherapeutics, Inc. (NYSEMKT:PLX) Ownership Structure Tell Us Something Useful?

Dec 10
Could The Protalix BioTherapeutics, Inc. (NYSEMKT:PLX) Ownership Structure Tell Us Something Useful?

Earnings and Revenue Growth Forecasts

NYSEAM:PLX - Analysts future estimates and past financials data (USD Millions)
DateRevenueEarningsFree Cash FlowCash from OpAvg. No. Analysts
12/31/2026167100N/AN/A1
12/31/202510155N/AN/A1
12/31/2024532N/AN/A1
9/30/202446-1078N/A
6/30/202438-15-4-3N/A
3/31/202460746N/A
12/31/2023658-2-1N/A
9/30/20236411-9-8N/A
6/30/2023679-11-10N/A
3/31/202341-16-23-22N/A
12/31/202248-15-26-25N/A
9/30/202248-18-28-27N/A
6/30/202245-18-21-20N/A
3/31/202243-24-8-6N/A
12/31/202138-28-12-10N/A
9/30/202149-21-14-13N/A
6/30/202148-21-16-14N/A
3/31/202153-14-30-29N/A
12/31/202063-7-27-26N/A
9/30/202061-7-23-22N/A
6/30/202065-6-23-22N/A
3/31/202066-9-20-19N/A
12/31/201955-18-20-19N/A
9/30/201947-24-20-20N/A
6/30/201945-26-3-3N/A
3/31/201938-26-6-6N/A
12/31/201834-26-8-8N/A
9/30/201828-341314N/A
6/30/201823-40N/A-10N/A
3/31/201825-32N/A-11N/A
12/31/201721-83N/A-10N/A
9/30/201719-73N/A-35N/A
6/30/201716-69N/A-28N/A
3/31/201711-80N/A-31N/A
12/31/20169-29N/A-32N/A
9/30/20167-35N/A-29N/A
6/30/20164-34N/A-34N/A
3/31/20163-29N/A-27N/A
12/31/20154-27N/A-24N/A
9/30/2015-6-31N/A-25N/A
6/30/2015-4-33N/A-26N/A
3/31/2015-2-32N/A-27N/A
12/31/20144-33N/A-29N/A
9/30/201415-32N/A-29N/A
6/30/201415-30N/A-28N/A
3/31/201415-31N/A-29N/A

Analyst Future Growth Forecasts

Earnings vs Savings Rate: PLX is forecast to become profitable over the next 3 years, which is considered faster growth than the savings rate (2.6%).

Earnings vs Market: PLX is forecast to become profitable over the next 3 years, which is considered above average market growth.

High Growth Earnings: PLX is expected to become profitable in the next 3 years.

Revenue vs Market: PLX's revenue (58.9% per year) is forecast to grow faster than the US market (9.2% per year).

High Growth Revenue: PLX's revenue (58.9% per year) is forecast to grow faster than 20% per year.

Earnings per Share Growth Forecasts

Future Return on Equity

Future ROE: Insufficient data to determine if PLX's Return on Equity is forecast to be high in 3 years time

Discover growth companies

7D

1Y

7D

1Y

7D

1Y

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2024/12/30 12:19
End of Day Share Price 2024/12/30 00:00
Earnings2024/09/30
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Protalix BioTherapeutics, Inc. is covered by 10 analysts. 1 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Ritu BaralCanaccord Genuity
Difei YangCapstone Investments
Peter WelfordJefferies LLC